The European Agency for the Evaluation of Medicinal Products
Evaluation of Medicines for Human Use

26 February 2001
EMEA/CPMP/571/01

WITHDRAWAL OF THE MARKETING AUTHORISATION FOR THE MEDICINAL PRODUCT "LIPROLOG – Insulin Lispro" EU/1/97/038/001-003

- On 7 May 1997, the European Commission issued a Marketing Authorisation valid throughout the European Union for the medicinal product Liprolog, which contains insulin lispro. The pharmaceutical company responsible for this medicinal product is Eli Lilly and Company Ltd.
- On 7 December 2000, the Marketing Authorisation holder notified the European Commission about the Marketing Authorisation holder's decision to withdraw the Marketing Authorisation for Liprolog.
- On 19 February 2001, the European Commission has adopted the decision withdrawing the Marketing Authorisation for the medicinal product for human use "LIPROLOG – Insulin lispro" EU/1/97/038/001-003. Pursuant to this decision the European Public Assessment Report for Liprolog has been removed from the EMEA website.
- For information, it should be noted that at present there is still a Marketing Authorisation valid throughout the European Union for the medicinal product Humalog, which contains insulin lispro. The pharmaceutical company responsible for this medicinal product is Eli Lilly and Company Ltd..

Mr Noel Wathion
Head of Unit
Post-Authorisation Evaluation Unit
Tel. (44-20) 74 18 85 92
Fax (44-20) 74 18 84 20

7 Westferry Circus, Canary Wharf, London, E14 4HB, UK
Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 86 13
E-mail: mail@emea.eudra.org http://www.emea.eu.int